Correction to: Durvalumab: A Review in Advanced Biliary Tract Cancer

被引：0
|
作者：
Simon Fung
Yahiya Y. Syed
机构：
[1] Springer Nature,
来源：
Targeted Oncology | 2024年 / 19卷 / 1期
关键词：
D O I：
10.1007/s11523-023-01021-0
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：129 / 129
相关论文
共 50 条
  • [1] Durvalumab: A Review in Advanced Biliary Tract Cancer
    Fung, Simon
    Syed, Yahiya Y.
    TARGETED ONCOLOGY, 2023, 18 (06) : 965 - 972
  • [2] Durvalumab: A Review in Advanced Biliary Tract Cancer
    Simon Fung
    Yahiya Y. Syed
    Targeted Oncology, 2023, 18 : 965 - 972
  • [3] Enhanced Potential of Durvalumab in the Initial Treatment of Advanced Biliary Tract Cancer
    Yasuda, Jungo
    Shiozaki, Hironori
    Sakamoto, Taro
    Futagawa, Yasuro
    Okamoto, Tomoyoshi
    Ikegami, Toru
    ANTICANCER RESEARCH, 2025, 45 (02) : 685 - 690
  • [4] Outcomes by antibiotic use in participants with advanced biliary tract cancer treated with durvalumab
    Pelzer, Uwe
    He, Aiwu R.
    Tan, Benjamin
    Suksombooncharoen, Thatthan
    Takahashi, Hidenori
    Chen, Ming-Huang
    Ostwal, Vikas
    Oh, Sang Cheul
    Sezer, Emel
    Potemski, Piotr
    Rau, Kun-Ming
    Sirachainan, Ekaphop
    Li, Junhe
    Blanc, Jean-Frederic
    Cohen, Gordon
    Zotkiewicz, Magdalena
    Rokutanda, Nana
    Oh, Do-Youn
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 75 - 75
  • [5] Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1)
    Choe, Jung Wan
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2023, 82 (02): : 105 - 106
  • [6] A new prognostic index for patients with advanced biliary tract cancer treated with cisplatin, gemcitabine and durvalumab
    Persano, M.
    Fornaro, L.
    Antonuzzo, L.
    Satake, T.
    Vandeputte, H.
    Lucchetti, J.
    Kim, J. W.
    Abidoye, O.
    Rapposelli, I. G.
    Tamberi, S.
    Finkelmeier, F.
    Giordano, G.
    Nicchetti, F.
    Chon, H. J.
    Yoo, C.
    Chan, S. L.
    Scartozzi, M.
    Lonardi, S.
    Rimassa, L.
    Gardini, A. Casadei
    ANNALS OF ONCOLOGY, 2024, 35 : S1465 - S1465
  • [7] Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
    Oh, Do-Youn
    He, Aiwu Ruth
    Qin, Shukui
    Chen, Li-Tzong
    Okusaka, Takuji
    Vogel, Arndt
    Kim, Jin Won
    Suksombooncharoen, Thatthan
    Lee, Myung Ah
    Kitano, Masayuki
    Burris, Howard
    Bouattour, Mohamed
    Tanasanvimon, Suebpong
    McNamara, Mairead G.
    Zaucha, Renata
    Avallone, Antonio
    Tan, Benjamin
    Cundom, Juan
    Lee, Choong-kun
    Takahashi, Hidenori
    Ikeda, Masafumi
    Chen, Jen-Shi
    Wang, Julie
    Makowsky, Mallory
    Rokutanda, Nana
    Zotkiewicz, Magdalena
    Kurland, John F.
    Cohen, Gordon
    Valle, Juan W.
    FUTURE ONCOLOGY, 2023, 19 (34) : 2277 - 2289
  • [8] Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date
    Storandt, Michael H.
    Jin, Zhaohui
    Mahipal, Amit
    ONCOTARGETS AND THERAPY, 2024, 17 : 383 - 394
  • [9] Economic evaluation for the US of durvalumab plus gemcitabine and cisplatin (DGC) in advanced biliary tract cancer (BTC)
    Aqel, Osama
    Shen, Yunrong
    Alfayoumi, Ibrahim
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] A phase II study of tremelimumab, durvalumab, and bevacizumab in advanced biliary tract cancers
    Coffman, Kelley Lauren
    Xie, Changqing
    Hrones, Donna M.
    Monge, B. M. Cecilia
    Kleiner, David E.
    Steinberg, Seth M.
    Redd, Bernadette
    Wood, Brad J.
    Kassin, Michael
    Levy, Elliot
    Benmebarek, Mohamed-Reda
    Greten, Tim F.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345